| 000 | 01432 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250516073338.0 | ||
| 264 | 0 | _c20120606 | |
| 008 | 201206s 0 0 eng d | ||
| 022 | _a1475-2840 | ||
| 024 | 7 |
_a10.1186/1475-2840-11-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCobble, Michael E | |
| 245 | 0 | 0 |
_aSaxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. _h[electronic resource] |
| 260 |
_bCardiovascular diabetology _cJan 2012 |
||
| 300 |
_a6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAdamantane _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aDiabetes Complications _xetiology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDipeptides _xadverse effects |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPatient Safety |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aFrederich, Robert | |
| 773 | 0 |
_tCardiovascular diabetology _gvol. 11 _gp. 6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1475-2840-11-6 _zAvailable from publisher's website |
| 999 |
_c21464021 _d21464021 |
||